Welcome to our dedicated page for Esperion Therapeutics SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Esperion Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Esperion Therapeutics's regulatory disclosures and financial reporting.
Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 11,824 shares of common stock. The shares were sold at an average price of $3.155 per share to satisfy tax obligations on recently vested restricted stock units. After this transaction, he continues to hold 667,524 shares directly.
Esperion Therapeutics, Inc. President and CEO Sheldon L. Koenig reported an open-market sale of 53,588 shares of common stock at an average price of $3.155 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units.
After this transaction, Koenig directly holds 2,119,111 shares of Esperion common stock, indicating he retains a substantial equity stake in the company despite the sale for tax purposes.
Esperion Therapeutics, Inc. Chief Financial Officer Benjamin Halladay reported an open-market sale of 10,773 shares of common stock at $3.155 per share. According to the filing, the shares were sold to satisfy tax obligations arising from vested restricted stock units. After this transaction, Halladay directly holds 702,829 shares, indicating he retains a substantial equity position in the company.
Esperion Therapeutics filed an amended current report to add detailed financial information for its acquisition of Corstasis Therapeutics, which closed on April 2, 2026. The deal is treated as an asset acquisition, with total cost of $83.389 million allocated mainly to Enbumyst, a developed product intangible valued at $77.097 million and amortized over 10 years.
The company funded the purchase with $75.0 million of new financing, including a $25.0 million term loan at 9.75% interest and a $50.0 million royalty sale tied to Otsuka payments until a $100.0 million cap is reached. Pro forma 2025 results show a combined net loss of $47.063 million, compared with Esperion’s standalone net loss of $22.682 million, reflecting added amortization and interest costs.
ESPR reported a Form 144 notice indicating 53,588 shares of Common Stock were listed for sale tied to restricted stock vesting on 06/16/2026 and designated as compensation. The filing also discloses a prior sale of 25,578 shares on 03/17/2026 for $69,551.70.
Benjamin Halladay filed a Form 144 reporting an intended resale of 10,773 shares of Common Stock tied to a restricted stock vesting event dated 06/15/2026. The filing also discloses 6,424 shares were sold on 03/17/2026.
ESPR submitted a Form 144 notice reporting a proposed sale of 11,824 shares of Common Stock tied to Restricted Stock Vesting, with an issuer designation dated 06/15/2026. The filing also records prior dispositions of 5,708 shares on 03/17/2026 for $15,427.58.
Esperion Therapeutics, Inc. reports that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS, expired at 11:59 p.m. Eastern Time on June 15, 2026.
The merger would make Esperion a wholly owned subsidiary of Essence Parent Inc. Completion still depends on other customary closing conditions in the Merger Agreement, including stockholder approval. A special virtual stockholder meeting to consider adoption of the Merger Agreement is scheduled for July 8, 2026 at 8:00 a.m. Eastern Time.
Esperion Therapeutics announced that Germany’s competition authority, the Bundeskartellamt, has cleared its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS. This removes a key regulatory condition under the German Act Against Restraints of Competition.
The merger would combine Esperion and Essence MergerCo Inc., with Esperion surviving as a wholly owned subsidiary of Parent. Completion still depends on remaining conditions, including expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and approval of the merger agreement by Esperion stockholders at a virtual special meeting scheduled for July 8, 2026.
Esperion Therapeutics reported a Schedule 13G disclosing that Glazer Capital, LLC and Paul J. Glazer hold 20,975,620 shares, representing 8.15% of common stock.
The filing states the shares are held by Glazer-managed funds with shared voting and dispositive power of 20,975,620 shares. The filing lists Glazer Capital Enhanced Master Fund, Ltd. as a holder with the right to receive proceeds. Signatures are dated 06/08/2026.